Default: Seminars in Oncology

ISSN: 0093-7754

Journal Home

Journal Guideline

Seminars in Oncology Q1 Unclaimed

W.B. Saunders Ltd United Kingdom
Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Seminars in Oncology is a journal indexed in SJR in Hematology and Oncology with an H index of 133. It has an SJR impact factor of 1,812 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 1,812.

Seminars in Oncology focuses its scope in these topics and keywords: breast, cancer, invasive, promising, role, smoking, systems, therapies, treatment, bone, ...

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy:

Type of publications:

Publication frecuency: -

Price

- €

Inmediate OA

NPD

Embargoed OA

- €

Non OA

Metrics

Seminars in Oncology

1,812

SJR Impact factor

133

H Index

51

Total Docs (Last Year)

150

Total Docs (3 years)

2969

Total Refs

690

Total Cites (3 years)

124

Citable Docs (3 years)

4,21

Cites/Doc (2 years)

58,22

Ref/Doc

Aims and Scope


breast, cancer, invasive, promising, role, smoking, systems, therapies, treatment, bone, patients, fungal, options, combined, delivery, paclitaxeltrastuzumab, paclitaxel, approaches, canceradvantages, cessationnew, combination, gemcitabinenovel, infectionsgemcitabine, liposomal, management, metastases, metastatic, oncologists,



Best articles by citations

How are bisphosphonates used today in breast cancer clinical practice?

View more

Therapeutic dilemmas with thalidomide in multiple myeloma: Case discussions

View more

Angiogenesis-dependent diseases

View more

The continuing problem of cardiac toxicity

View more

Docetaxel (Taxotere) in combination with platinums in patients with non[ndash ]small cell lung cancer: Trial data and implications for clinical management

View more

Temozolomide for recurrent high-grade glioma

View more

Docetaxel (Taxotere) in combination with radiation therapy and the potential of weekly administration in elderly and/or poor performance status patients with advanced non[ndash ]small cell lung cancer

View more

Temozolomide for treating brain metastases

View more

Docetaxel (Taxotere) in the treatment of non[ndash ]small cell lung cancer: An international update

View more

Temozolomide in combination with other cytotoxic agents

View more

Docetaxel (taxotere) plus trastuzumab (herceptin) in breast cancer

View more

The role of nuclear factor-[kappa ]B in the biology and treatment of multiple myeloma

View more
SHOW MORE ARTICLES

Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non[ndash ]small cell lung cancer: A review of two phase III trials

View more

Docetaxel and exisulind in hormone-refractory prostate cancer

View more

Extending preclinical models of skeletal manifestations of malignancy to the clinical setting

View more

Docetaxel followed by hormone therapy after failure of definitive treatments for clinically localized/locally advanced prostate cancer: Preliminary results

View more

Cancer immunotherapy with natural killer cells

View more

Dosing regimens and main adverse events of bisphosphonates

View more

Pharmacokinetic profiles of doxorubicin in combination with taxanes

View more

Docetaxel in the treatment of prostate cancer: Opportunities for combination regimens and challenges to development

View more

Cancer in older persons: an international issue in an aging world

View more

Bisphosphonates in oncology: Breast cancer and beyond

View more

Bisphosphonates in the prevention of bone metastases: Current evidence

View more

Docetaxel, estramustine, and short-term androgen withdrawal for patients with biochemical failure after definitive local therapy for prostate cancer

View more

Comments

No comments ... Be the first to comment!

FAQS